Go back

Report urges Finnish life sciences reform

Finnish health and pharmaceutical R&D needs reform in order to become internationally competitive and fuel economic growth, a report says.

The report, published on 4 December, was commissioned by the Ministry of Employment and the Economy and authored by Mikko Alkio from Avance Attorneys.

Finland has not succeeded in commercialising its knowledge in health and pharmaceuticals, the report says. The country is a net importer in the health sector, and has fallen behind neighbours Sweden and Denmark.

Finland’s public sector spends between €300 and €400 million on health R&D each year. But the country’s health research infrastructure and funding are fragmented. This has a negative effect on the ability of the private sector to collaborate with public research institutes, the report says.

The report wants Finland’s government to write a national strategy for life sciences to help to streamline funding and research. The country should also invest in a new cancer research centre as well as up to four other therapy, research and innovation clusters.